- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | Conexeu Sciences Inc.: The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It | 1 | GlobeNewswire (USA) | ||
| 09.07. | One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics | 4 | CNW | ||
| 07.07. | Conexeu Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| CONEXEU SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.07. | Conexeu Sciences Inc.: A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill | 1 | GlobeNewswire (USA) | ||
| 25.06. | Conexeu Sciences Inc.: Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform | 1 | GlobeNewswire (USA) | ||
| 22.06. | Conexeu Sciences stock initiated at buy by H.C. Wainwright, $20 target | 1 | Investing.com | ||
| 15.06. | Conexeu Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.06. | Conexeu Sciences Inc.: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing | 221 | GlobeNewswire (Europe) | RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced additions to... ► Artikel lesen | |
| 09.06. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Conexeu Sciences: Aktie legt nach Fortschritten bei Wundversorgungs-Produkt zu | 1 | Investing.com Deutsch | ||
| 08.06. | Conexeu forciert Produktionsaufbau für Wundpflege-Produkt vor geplantem FDA-Antrag 2027 | - | Investing.com Deutsch | ||
| 08.06. | Conexeu Sciences Inc.: Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program | 1 | GlobeNewswire (USA) | ||
| 03.06. | Conexeu Sciences Inc.: Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 21.05. | Conexeu Sciences Inc.: Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU" | 512 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially... ► Artikel lesen | |
| 19.05. | Conexeu Sciences Inc.: Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants | 483 | Newsfile | Conexeu's B.R.E.A.S.T. was developed using the Company's proprietary CXU regenerative tissue platform to support gradual tissue remodelingDesigned as a resorbable, bioregenerative tissue matrix... ► Artikel lesen | |
| 14.05. | Conexeu Sciences Inc.: Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration | 462 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular... ► Artikel lesen | |
| 12.05. | Medical device developer Conexeu Sciences set to direct list on the Nasdaq on May 21 | 1 | Renaissance Capital | ||
| 11.05. | Conexeu Sciences Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 17.04. | Conexeu Sciences Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 06.04. | Conexeu Sciences Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO-DIAGNOSTICS | 1,440 | 0,00 % | EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test | ||
| CYTOSORBENTS | 0,324 | +1,89 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,600 | -0,28 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| FULGENT GENETICS | 14,500 | +1,40 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| EMBECTA | 3,159 | -0,06 % | Picard Medical, Inc.: Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026 | ||
| CHECK-CAP | 0,915 | -1,61 % | Humanoid Global meldet Fortschritte von MBody AI bei der kommerziellen Expansion und dem geplanten Unternehmenszusammenschluss mit Check-Cap | Vancouver, BC / 14. Juli 2026 / IRW-Press / Humanoid Global
Holdings Corp. ("Humanoid Global" oder das "Unternehmen")
(CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), ein börsennotierter
Investment-Emittent... ► Artikel lesen | |
| ELECTROCORE | 5,150 | -3,74 % | electroCore, Inc.: electroCore Announces Full Year 2025 Financial Results and Organizational Changes | Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness... ► Artikel lesen | |
| CATHETER PRECISION | 0,254 | 0,00 % | Catheter Precision, Inc. - 8-K, Current Report | ||
| CLEARPOINT NEURO | 14,950 | +0,07 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy Designation for Sasineprocel | RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire... ► Artikel lesen | |
| ENVUE MEDICAL | 0,318 | +0,76 % | ENvue Medical, Inc.: ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform | Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing... ► Artikel lesen | |
| FIREFLY NEUROSCIENCE | 1,040 | -2,80 % | Firefly Neuroscience, Inc.: Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides | ||
| ENDRA LIFE SCIENCES | 4,700 | -1,47 % | ASP Isotopes Inc.: ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing | Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project Listing expected to provide investors with direct exposure to one of... ► Artikel lesen | |
| FEMASYS | 2,850 | 0,00 % | Femasys Inc.: Femasys Regains Compliance with Nasdaq Listing Requirements | ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective... ► Artikel lesen | |
| CUPRINA HOLDINGS | 2,930 | +0,34 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| EXAGEN | 3,880 | -3,00 % | Exagen Inc. Reports First Quarter 2026 Results | CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026... ► Artikel lesen |
Das Unternehmen CONEXEU SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 8,370 Euro und damit +0,72 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CONEXEU SCIENCES INC finden Sie auf Wallstreet Online.